The Implication of Cardiac Injury Score on In-hospital Mortality of Coronavirus Disease 2019
© 2020 The Korean Academy of Medical Sciences..
BACKGROUNDS: The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has spread worldwide. Cardiac injury after SARS-CoV-2 infection is a major concern. The present study investigated impact of the biomarkers indicating cardiac injury in coronavirus disease 2019 (COVID-19) on patients' outcomes.
METHODS: This study enrolled patients who were confirmed to have COVID-19 and admitted at a tertiary university referral hospital between February 19, 2020 and March 15, 2020. Cardiac injury was defined as an abnormality in one of the following result markers: 1) myocardial damage marker (creatine kinase-MB or troponin-I), 2) heart failure marker (N-terminal-pro B-type natriuretic peptide), and 3) electrical abnormality marker (electrocardiography). The relationship between each cardiac injury marker and mortality was evaluated. Survival analysis of mortality according to the scoring by numbers of cardiac injury markers was also performed.
RESULTS: A total of 38 patients with COVID-19 were enrolled. Twenty-two patients (57.9%) had at least one of cardiac injury markers. The patients with cardiac injuries were older (69.6 ± 14.9 vs. 58.6 ± 13.9 years old, P = 0.026), and were more male (59.1% vs. 18.8%, P = 0.013). They showed lower initial oxygen saturation (92.8 vs. 97.1%, P = 0.002) and a trend toward higher mortality (27.3 vs. 6.3%, P = 0.099). The increased number of cardiac injury markers was significantly related to a higher incidence of in-hospital mortality which was also evidenced by Kaplan-Meier survival analysis (P = 0.008).
CONCLUSION: The increased number of cardiac injury markers is related to in-hospital mortality in patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Journal of Korean medical science - 35(2020), 39 vom: 12. Okt., Seite e349 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, In Cheol [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.10.2020 Date Revised 18.09.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3346/jkms.2020.35.e349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316155489 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316155489 | ||
| 003 | DE-627 | ||
| 005 | 20231225160453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3346/jkms.2020.35.e349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316155489 | ||
| 035 | |a (NLM)33045772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, In Cheol |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Implication of Cardiac Injury Score on In-hospital Mortality of Coronavirus Disease 2019 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2020 | ||
| 500 | |a Date Revised 18.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Korean Academy of Medical Sciences. | ||
| 520 | |a BACKGROUNDS: The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has spread worldwide. Cardiac injury after SARS-CoV-2 infection is a major concern. The present study investigated impact of the biomarkers indicating cardiac injury in coronavirus disease 2019 (COVID-19) on patients' outcomes | ||
| 520 | |a METHODS: This study enrolled patients who were confirmed to have COVID-19 and admitted at a tertiary university referral hospital between February 19, 2020 and March 15, 2020. Cardiac injury was defined as an abnormality in one of the following result markers: 1) myocardial damage marker (creatine kinase-MB or troponin-I), 2) heart failure marker (N-terminal-pro B-type natriuretic peptide), and 3) electrical abnormality marker (electrocardiography). The relationship between each cardiac injury marker and mortality was evaluated. Survival analysis of mortality according to the scoring by numbers of cardiac injury markers was also performed | ||
| 520 | |a RESULTS: A total of 38 patients with COVID-19 were enrolled. Twenty-two patients (57.9%) had at least one of cardiac injury markers. The patients with cardiac injuries were older (69.6 ± 14.9 vs. 58.6 ± 13.9 years old, P = 0.026), and were more male (59.1% vs. 18.8%, P = 0.013). They showed lower initial oxygen saturation (92.8 vs. 97.1%, P = 0.002) and a trend toward higher mortality (27.3 vs. 6.3%, P = 0.099). The increased number of cardiac injury markers was significantly related to a higher incidence of in-hospital mortality which was also evidenced by Kaplan-Meier survival analysis (P = 0.008) | ||
| 520 | |a CONCLUSION: The increased number of cardiac injury markers is related to in-hospital mortality in patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19, Cardiac Injury Markers | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a In-hospital Mortality | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Troponin I |2 NLM | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 650 | 7 | |a Creatine Kinase, MB Form |2 NLM | |
| 650 | 7 | |a EC 2.7.3.2 |2 NLM | |
| 700 | 1 | |a Song, Jin Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hee Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jeong Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Hyun, Miri |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Ji Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyun Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Yong Shik |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jae Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Youn, Jong Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Jongmin |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Cheol Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Yun Kyeong |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hyoung Seob |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Hyuck Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Nam, Chang Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Seongwook |e verfasserin |4 aut | |
| 700 | 1 | |a Hur, Seung Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Eisen, Howard J |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyungseop |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Korean medical science |d 1995 |g 35(2020), 39 vom: 12. Okt., Seite e349 |w (DE-627)NLM012649317 |x 1598-6357 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g number:39 |g day:12 |g month:10 |g pages:e349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3346/jkms.2020.35.e349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |e 39 |b 12 |c 10 |h e349 | ||